{"schema_version":"secwatch.filing_event.v1","accession":"0001658247-26-000003","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2026-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.787616+00:00","generated_at":"2026-05-16T07:57:33.230817+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Crinetics changes Jeff Knight's title from COO to Chief Development and Operating Officer","bullets":["Title change effective January 2, 2026; responsibilities expanded.","No change to Jeff Knight's compensation arrangements.","No arrangements or family relationships with other executives or directors.","Business experience described in prior proxy statement remains unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001658247-26-000003","json":"https://secwatch.observer/filing/0001658247-26-000003.json","markdown":"https://secwatch.observer/filing/0001658247-26-000003.md","text":"https://secwatch.observer/filing/0001658247-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000003/0001658247-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000003/crnx-20260120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:57:33.230817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}